Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The investment will facilitate the creation of a cross-industry synergistic environment for the development and production of ADC platforms including, PINOT-ADC™, a next-generation ADC anti-cancer drug platform developing PBX-001 (sacituzumab), targeting solid cancer Trop2.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: PBX-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: PINOTBIO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 21, 2023